---
company: HEALTHEQUITY, INC.
ticker: HQY
form: 8-K
filed: 2026-05-28
accession: 0001428336-26-000027
source: https://www.sec.gov/Archives/edgar/data/1428336/000142833626000027/
---

# Healthequity (HQY) earnings release, May 28, 2026

Healthequity, Inc. (HQY) · Form 8-K, Item 2.02 · Filed 2026-05-28 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1428336/000142833626000027/)

HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results

Raises Guidance

Increases Repurchase Program by $1.0 Billion

Highlights of the first quarter include:

• Net income increased

29% to

$69.4 million, and net income margin increased to

20% from

16% last year.

• Adjusted EBITDA increased

17% to

$164.5 million, and Adjusted EBITDA margin increased to

46% from

42% last year.

• Revenue increased

7% to

$354.6 million.

• Net income per diluted share rose

34% to

$0.82 from

$0.61 one year ago, and non-GAAP net income per diluted share increased

28% to

$1.24.

• Total HSA Assets grew

19% to

$37.1 billion.

• Returned

$123.0 million to shareholders through stock repurchases.

Draper, Utah – May 28, 2026 – HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its first quarter ended April 30, 2026.

"HealthEquity delivered strong first‑quarter results, with Adjusted EBITDA margin expanding to 46% and a raised fiscal 2027 outlook," said Scott Cutler, President and CEO of HealthEquity. "These results demonstrate that our flywheel is compounding through account and asset growth, deeper member engagement, technology‑enabled efficiency, and increasing operating leverage. As healthcare affordability structurally shifts more responsibility to consumers, demand for trusted healthcare financial solutions continues to expand. Our authorization of an additional $1 billion under our share repurchase program reflects our confidence in the durability and long-term cash-generating power of our model."

HealthEquity’s growth model is built on two reinforcing drivers: growth in member accounts and their HSA Assets over time and expansion in the lifetime value of each member relationship as engagement and activity increase. As accounts mature, these dynamics can compound, supporting durable growth and margin expansion while reducing reliance on short-term employment trends and new account additions in any single period.

First quarter financial results

Revenue for the first quarter ended April 30, 2026 was $354.6 million, an increase of 7% compared to $330.8 million for the first quarter ended April 30, 2025. Revenue this quarter included: service revenue of $122.9 million, custodial revenue of $174.3 million, and interchange revenue of $57.4 million.

Net income was $69.4 million, or $0.82 per diluted share, for the first quarter ended April 30, 2026, compared to $53.9 million, or $0.61 per diluted share, for the first quarter ended April 30, 2025. Net income margin was 20% for the first quarter ended April 30, 2026, compared to 16% for the first quarter ended April 30, 2025.

Non-GAAP net income was $105.1 million, or $1.24 per diluted share, for the first quarter ended April 30, 2026, compared to $85.8 million, or $0.97 per diluted share, for the first quarter ended April 30, 2025.

Adjusted EBITDA was $164.5 million for the first quarter ended April 30, 2026, an increase of 17% compared to the first quarter ended April 30, 2025. Adjusted EBITDA was 46% of revenue, compared to 42% for the first quarter ended April 30, 2025.

Account and asset metrics

HSAs as of April 30, 2026 were 10.6 million, an increase of 8% year over year, including 909,000 HSAs with investments, an increase of 18% year over year. Total Accounts as of April 30, 2026 were 17.8 million, including 7.2 million complementary CDBs.

Total HSA Assets as of April 30, 2026 were $37.1 billion, an increase of 19% year over year. Total HSA Assets included $17.5 billion of HSA cash and $19.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $1.0 billion as of April 30, 2026.¹

Stock repurchase program

The Company repurchased 1.5 million shares of its common stock for $123.0 million during the first quarter ended April 30, 2026. In May 2026, the Company's board of directors authorized an additional $1.0 billion of common stock repurchases under the program.

Business outlook

For the fiscal year ending January 31, 2027, management expects revenues of $1.410 billion to $1.420 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.95 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $625 million to $633 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Thursday, May 28, 2026 to discuss the fiscal 2027 first quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

• ... (truncated)er integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.

• Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.

• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.²

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;

• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;

• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;

• the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;

• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;

• the significant competition we face and may face in the future, including from those with greater resources than us;

• our reliance on the availability and performance of our technology and communications systems;

• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;

• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;

• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;

• our reliance on partners and third-party vendors for distribution and important services;

• our ability to develop and implement updated features for our technology platforms and communications systems; and

• our reliance on our management team and key team members.... (truncated)tive of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact

Richard Putnam

801-727-1000 rputnam@healthequity.com³

HealthEquity, Inc. and subsidiaries

Condensed consolidated balance sheets⁴

HealthEquity, Inc. and subsidiaries

Condensed consolidated statements of operations (unaudited)⁵

HealthEquity, Inc. and subsidiaries

Condensed consolidated statements of comprehensive income (unaudited)⁶

HealthEquity, Inc. and subsidiaries

Condensed consolidated statements of cash flows (unaudited)⁷

HealthEquity, Inc. and subsidiaries

Condensed consolidated statements of cash flows (unaudited) (continued)

Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

Total Accounts (unaudited)

*

Not meaningful

HSA Assets (unaudited)⁸

HSA cash maturity schedule

The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of April 30, 2026:

(1)

Excludes $1.0 billion of HSA cash held in floating-rate contracts as of April 30, 2026.

Client-held funds (unaudited)

Reconciliation of net income to Adjusted EBITDA (unaudited)

Net income and Adjusted EBITDA as a percentage of revenue (unaudited)⁹

Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)

Note: Values presented may not calculate due to rounding.

Reconciliation of net income to non-GAAP net income (unaudited)

(1)

The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.¹⁰

Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

Note: Values presented may not calculate due to rounding.

(1)

The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.¹¹

Certain terms¹²

## Financial statements

### Income Statement (Three months ended April 30, — Condensed consolidated statements of operations (unaudited) (in thousands, except per share data))

| | Three months ended April 30, – 2026 | Three months ended April 30, – 2025 |
|---|---:|---:|
| Service revenue | 122,932 | 119,784 |
| Custodial revenue | 174,334 | 156,455 |
| Interchange revenue | 57,375 | 54,605 |
| Total revenue | 354,641 | 330,844 |
| Cost of revenue | Service costs | 78,326 | 88,005 |
| Cost of revenue | Custodial costs | 11,655 | 10,747 |
| Cost of revenue | Interchange costs | 8,348 | 7,781 |
| Cost of revenue | Total cost of revenue | 98,329 | 106,533 |
| Cost of revenue | Gross profit | 256,312 | 224,311 |
| Operating expenses | Sales and marketing | 26,833 | 25,984 |
| Operating expenses | Technology and development | 67,767 | 61,436 |
| Operating expenses | General and administrative | 31,131 | 25,536 |
| Operating expenses | Amortization of acquired intangible assets | 26,515 | 27,002 |
| Operating expenses | Merger integration | 1,113 | 1,275 |
| Operating expenses | Total operating expenses | 153,359 | 141,233 |
| Operating expenses | Income from operations | 102,953 | 83,078 |
| Other expense | Interest expense | -12,588 | -14,858 |
| Other expense | Other income, net | 2,048 | 2,733 |
| Other expense | Total other expense | -10,540 | -12,125 |
| Other expense | Income before income taxes | 92,413 | 70,953 |
| Other expense | Income tax provision | 22,995 | 17,038 |
| Other expense | Net income | 69,418 | 53,915 |
| Net income per share: | Basic | 0.82 | 0.62 |
| Net income per share: | Diluted | 0.82 | 0.61 |
| Weighted-average number of shares used in computing net income per share: | Basic | 84,413 | 86,655 |
| Weighted-average number of shares used in computing net income per share: | Diluted | 85,006 | 88,415 |

### Income Statement (Three months ended April 30, — Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows: (in thousands))

| | Three months ended April 30, – 2026 | Three months ended April 30, – 2025 |
|---|---:|---:|
| Cost of revenue | 2,787 | 3,387 |
| Sales and marketing | 4,524 | 4,870 |
| Technology and development | 3,953 | 5,920 |
| General and administrative | 8,142 | 159 |
| Total stock-based compensation expense | 19,406 | 14,336 |

### Income Statement (Three months ended April 30, — Reconciliation of net income to Adjusted EBITDA (unaudited) (in thousands))

| | Three months ended April 30, – 2026 | Three months ended April 30, – 2025 |
|---|---:|---:|
| Net income | 69,418 | 53,915 |
| Interest income | -1,887 | -2,733 |
| Interest expense | 12,588 | 14,858 |
| Income tax provision | 22,995 | 17,038 |
| Depreciation and amortization | 11,699 | 11,739 |
| Amortization of acquired intangible assets | 26,515 | 27,002 |
| Stock-based compensation expense | 19,406 | 14,336 |
| Merger integration expenses | 1,113 | 1,275 |
| Amortization of incremental costs to obtain a contract | 2,116 | 1,926 |
| Costs associated with unused office space | 686 | 852 |
| Other | -161 |  |
| Adjusted EBITDA | 164,488 | 140,208 |

### Income Statement (Three months ended April 30, — Net income and Adjusted EBITDA as a percentage of revenue (unaudited) (in thousands, except percentages))

| | Three months ended April 30, – 2026 | Three months ended April 30, – 2025 | $ Change | % Change |
|---|---:|---:|---:|---:|
| Net income | 69,418 | 53,915 | 15,503 | 29.0% |
| As a percentage of revenue | 20 | 16 |  |  |
| Adjusted EBITDA | 164,488 | 140,208 | 24,280 | 17.0% |
| As a percentage of revenue | 46 | 42 |  |  |

### Income Statement (Outlook for the year ending — Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited) (in millions))

| | Outlook for the year ending – January 31, 2027 |
|---|---:|
| Net income | $242 - 248 |
| Interest income | -6 |
| Interest expense | 50 |
| Income tax provision | 81 - 83 |
| Depreciation and amortization | 50 |
| Amortization of acquired intangible assets | 104 |
| Stock-based compensation expense | 87 |
| Merger integration expenses | 6 |
| Amortization of incremental costs to obtain a contract | 9 |
| Costs associated with unused office space | 3 |
| Adjusted EBITDA | $625 - 633 |

### Balance Sheet (April 30, 2026 — Condensed consolidated balance sheets (in thousands, except par value))

| | April 30, 2026 – (unaudited) | January 31, 2026 |
|---|---:|---:|
| Cash and cash equivalents | 265,369 | 318,927 |
| Accounts receivable, net of allowance for doubtful accounts of $953 and $924 as of April 30, 2026 and January 31, 2026, respectively | 122,003 | 123,696 |
| Prepaid expenses and other current assets | 79,156 | 69,658 |
| Total current assets | 466,528 | 512,281 |
| Property and equipment, net | 3,800 | 3,177 |
| Operating lease right-of-use assets | 34,578 | 36,310 |
| Intangible assets, net | 1,073,045 | 1,097,172 |
| Goodwill | 1,648,145 | 1,648,145 |
| Other assets | 80,090 | 83,247 |
| Total assets | 3,306,186 | 3,380,332 |
| Current liabilities | Accounts payable | 14,219 | 12,159 |
| Current liabilities | Accrued compensation | 26,664 | 60,392 |
| Current liabilities | Accrued liabilities | 84,941 | 74,388 |
| Current liabilities | Operating lease liabilities | 9,916 | 9,911 |
| Current liabilities | Total current liabilities | 135,740 | 156,850 |
| Long-term liabilities | Long-term debt, net of issuance costs | 942,656 | 957,379 |
| Long-term liabilities | Operating lease liabilities, non-current | 32,110 | 34,190 |
| Long-term liabilities | Other long-term liabilities | 52,932 | 31,007 |
| Long-term liabilities | Deferred tax liability | 95,353 | 93,710 |
| Long-term liabilities | Total long-term liabilities | 1,123,051 | 1,116,286 |
| Long-term liabilities | Total liabilities | 1,258,791 | 1,273,136 |
| Stockholders’ equity | Common stock, $0.0001 par value, 900,000 shares authorized, 83,927 and 85,007 shares issued and outstanding as of April 30, 2026 and January 31, 2026, respectively | 8 | 8 |
| Stockholders’ equity | Additional paid-in capital | 1,901,935 | 1,916,989 |
| Stockholders’ equity | Accumulated earnings | 177,204 | 195,906 |
| Stockholders’ equity | Accumulated other comprehensive loss | -31,752 | -5,707 |
| Stockholders’ equity | Total stockholders’ equity | 2,047,395 | 2,107,196 |

### Cash Flow (Three months ended April 30, — Condensed consolidated statements of cash flows (unaudited) (in thousands))

| | Three months ended April 30, – 2026 | Three months ended April 30, – 2025 |
|---|---:|---:|
| Net income | 69,418 | 53,915 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 38,214 | 38,741 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation | 19,406 | 14,336 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of debt discount and issuance costs | 277 | 265 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of gains on derivatives | -196 |  |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred taxes | 10,106 | 1,324 |
| Changes in operating assets and liabilities: | Accounts receivable, net | 1,693 | 1,750 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current and non-current assets | -11,690 | -5,702 |
| Changes in operating assets and liabilities: | Operating lease right-of-use assets | 1,732 | 1,649 |
| Changes in operating assets and liabilities: | Accrued compensation | -31,242 | -42,210 |
| Changes in operating assets and liabilities: | Accounts payable, accrued liabilities, and other current liabilities | -873 | 3,422 |
| Changes in operating assets and liabilities: | Operating lease liabilities, non-current | -2,080 | -1,968 |
| Changes in operating assets and liabilities: | Other long-term liabilities | 2,761 | -784 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 97,526 | 64,738 |
| Cash flows from investing activities: | Purchases of software and capitalized software development costs | -15,930 | -16,057 |
| Cash flows from investing activities: | Purchases of property and equipment | -362 | -86 |
| Cash flows from investing activities: | Settlement of derivatives, net | 2,388 |  |
| Cash flows from investing activities: | Net cash used in investing activities | -13,904 | -16,143 |
| Cash flows from financing activities: | Repurchases of common stock | -123,314 | -59,065 |
| Cash flows from financing activities: | Principal payments on long-term debt | -15,000 |  |
| Cash flows from financing activities: | Settlement of client-held funds obligation, net | 716 | 1,451 |
| Cash flows from financing activities: | Proceeds from exercise of common stock options | 418 | 965 |
| Cash flows from financing activities: | Net cash used in financing activities | -137,180 | -56,649 |
| Cash flows from financing activities: | Decrease in cash and cash equivalents | -53,558 | -8,054 |
| Cash flows from financing activities: | Beginning cash and cash equivalents | 318,927 | 295,948 |
| Cash flows from financing activities: | Ending cash and cash equivalents | 265,369 | 287,894 |
